Axillary Hyperhidrosis Pipeline Drugs 2024 | Glaxosmithkline, Medytox, Theravida, Candesant Biomedical

(MENAFN- GetNews)

DelveInsight's,
“Axillary Hyperhidrosis Pipeline Insight 2024”
report provides comprehensive insights about
3+ companies and 3+ pipeline drugs
in Axillary Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Axillary Hyperhidrosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Axillary Hyperhidrosis Pipeline Outlook

Key Takeaways from the Axillary Hyperhidrosis Pipeline Report

• January 2024:- InMode MD Ltd.- The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae.
• DelveInsight's Axillary Hyperhidrosis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Axillary Hyperhidrosis treatment.
• The leading Axillary Hyperhidrosis Companies such as GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical, and others.
• Promising Axillary Hyperhidrosis Therapies such as Sofpironium bromide, ET-01, DMT410, and others.

Stay ahead with the most recent pipeline outlook for Axillary Hyperhidrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Axillary Hyperhidrosis Treatment Drugs

Axillary Hyperhidrosis Emerging Drugs

• Sofpironium bromide: Brickell Biotech Inc.

Sofpironium bromide is a new chemical entity that we are currently developing in the U.S. as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The drug is a retro metabolically designed anticholinergic agent which selectively binds to M3 AC receptor potentially inhibiting sweat production.

• ET-01: Eirion Therapeutics

ET-01 is a topical botulinum product being developed with the goal of avoiding the pain, bleeding and bruising that can be associated with the injection of commercially available botulinum products. ET-01 employs a nanoemulsion transdermal delivery technology essential for a large molecule such as botulinum to penetrate into the skin drug is currently being developed in Phase 2 stage of development for the treatment of Axillary Hyperhidrosis.

• DMT410: Dermata Therapeutics LLC pipeline

DMT410 is the second development program using DMT400 combination regimen in combination with botulinum toxin. Dermata Therapeutics have completed a proof of concept, Phase 1 clinical trial using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis. The treatment was well tolerated, and a majority of patients saw a reduction in sweat production similar to results seen from using injections of BOTOX®.

Explore groundbreaking therapies and clinical trials in the Axillary Hyperhidrosis Pipeline. Access DelveInsight's detailed report now! @ New Axillary Hyperhidrosis Drugs

Axillary Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Axillary Hyperhidrosis Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Unveil the future of Axillary Hyperhidrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Axillary Hyperhidrosis Market Drivers and Barriers

Scope of the Axillary Hyperhidrosis Pipeline Report

• Coverage- Global
• Axillary Hyperhidrosis Companies- GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical, and others.
• Axillary Hyperhidrosis Therapies- Sofpironium bromide, ET-01, DMT410, and others.
• Axillary Hyperhidrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Axillary Hyperhidrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Axillary Hyperhidrosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Axillary Hyperhidrosis Companies, Key Products and Unmet Needs

Table of Content